



ESMO

Unlocking the Future of Cancer Care: ESMO 2024's Groundbreaking Innovations

BY: JONATHAN GOUGH
SVP, DIRECTOR OF BRAND STRATEGY AT WILDTYPE HEALTH,
AN OMNICOM HEALTH GROUP COMPANY

OCTOBER 2024

ohg
Omnicom Health Group

Unlocking the Future of Cancer Care: ESMO 2024's Groundbreaking Innovations

The European Society for Medical Oncology (ESMO) 2024 Congress, held in Barcelona, brought together a global community of oncologists, researchers, and healthcare professionals to discuss the latest breakthroughs in cancer care. This year's theme, "Science and Beyond," emphasized the need for massive collaboration and innovation, spanning topics such as cancer prevention, clinical trials, the integration of AI, and emerging therapies. ESMO 2024 was a forum for presenting groundbreaking data and fostering multidisciplinary debate, with a focus on improving patient outcomes.


A key highlight of the congress was its emphasis on novel therapeutic strategies, particularly in immunotherapy; targeted therapies like antibody drug conjugates (ADCs); and the rising significance of early-onset cancer. The event also spotlighted the use of artificial intelligence (AI) to drive precision oncology, providing a glimpse into the future of cancer care. Our team at Omnicom Health Group (OHG) were active participants, gaining valuable insights from these discussions to better understand how these innovations will shape the future of oncology.

Here are the key takeaways from ESMO 2024 that we believe will be crucial moving forward

Immunotherapy: Expanding Horizons Across Cancer Types

While the KEYNOTE-522 trial has been a cornerstone of recent discussions around triple-negative breast cancer, ESMO 2024 presented a much broader landscape of immunotherapy trials. For instance, the KEYNOTE-A18 trial showcased significant overall survival benefits in advanced cervical cancer, positioning pembrolizumab as a new standard of care. Additionally, the NIAGARA trial revealed the efficacy of durvalumab in muscle-invasive bladder cancer, with event-free survival benefits that suggest its potential as a new perioperative treatment standard.

These trials demonstrate how immunotherapy is transforming cancer care across a range of diseases, making what were once terminal conditions more manageable and offering long-term hope. The landscape of immunotherapy is growing rapidly, and we can expect more breakthroughs as research continues to refine and expand its applications.



Unlocking the Future of Cancer Care: ESMO 2024's Groundbreaking Innovations (cont.)

Antibody Drug Conjugates (ADCs): Redefining Precision

Antibody Drug Conjugates (ADCs) are no longer emerging therapies; they are now firmly established as a leading innovation in cancer care. At ESMO 2024, several sessions highlighted the advancements of third-generation ADCs, which offer enhanced targeting mechanisms and reduced side effects compared with earlier versions. For instance, the PIONeeR trial focused on overcoming resistance to programmed cell death ligand 1 inhibitors in advanced non-small cell lung cancer (NSCLC), showcasing how ADCs can be used in combination with immunotherapies to improve treatment outcomes.

This evolution in ADC technology continues to push the boundaries of precision medicine, allowing for more effective treatments that minimize damage to healthy tissues. As ADCs continue to evolve, their role in treating a variety of cancers will only expand.

AI and Digital Oncology: Unlocking the Future

AI is poised to transform oncology, and ESMO 2024 offered insights into how AI is being integrated into cancer care. The potential for AI to analyze large data sets—combining clinical, genomic, and imaging data—opens up new possibilities for precision medicine. One of the most promising developments is the use of AI biomarkers, which could help identify treatment resistance pathways. As AI continues to mature, it will drive more personalized and data-driven approaches to oncology, although, careful oversight will be needed to ensure reliability.



Unlocking the Future of Cancer Care: ESMO 2024's Groundbreaking Innovations (cont.)

Early-Onset Cancer: A Global Challenge

One of the more concerning trends highlighted at ESMO 2024 is the rising incidence of early-onset cancers, particularly in adults under 50. These cancers, which include breast, colorectal, and liver cancers, have been linked to lifestyle and environmental factors. The conference emphasized the need for precision prevention strategies that take both genetic and lifestyle factors into account. For healthcare professionals and marketers alike, this trend underscores the importance of early detection and education campaigns aimed at younger populations.

De-escalation of Cancer Treatments: Optimizing for Broader Access

De-escalation strategies, particularly in immunotherapy, were a significant focus at ESMO 2024. However, this approach requires a delicate balance between patient access and industry sustainability. Studies like the DEDICATION-1 trial, which examined lower-dose regimens of pembrolizumab for NSCLC, offer potential pathways for broader patient access at reduced costs; yet, this trend poses challenges for the industry to find new ways to demonstrate the value of newer therapies in the face of rising healthcare costs. While this approach may prove beneficial for patients, it's something the pharmaceutical industry will need to monitor closely as the trend grows.



Driving the Future of Oncology with OHG

As we look to the future, it's clear that the innovations presented at ESMO 2024 will have a lasting impact on cancer care. From advancements in immunotherapy and ADCs to the integration of AI in oncology, these trends are shaping a new era of precision medicine and broader access to life-saving treatments. At OHG, we are committed to staying at the forefront of these developments, helping our partners navigate the evolving landscape of oncology and adapt to these breakthroughs.

Our ambition is to be the case study that others emulate. By embracing cutting-edge technologies and innovative treatment approaches, we aim to set the standard for excellence in healthcare marketing and communication. We believe in challenging the status quo, pushing the boundaries of what's possible, and creating solutions that not only impact patients today but also shape the future of oncology for generations to come.

For More Information



Jonathan Gough
SVP, Director of Brand
Strategy at
Wildtype Health



Tracy Martin
VP, Account Director at
Wildtype Health



Valeria Carter
Senior Medical
Strategist at
Wildtype Health



Near Bhalavat
Senior Medical
Strategist at
Wildtype Health

The insights shared in this article were gathered by OHG's team of experts who attended ESMO 2024, including key contributors from Wildtype Health: **Jonathan Gough**, SVP, Director of Strategy; **Tracy Martin**, VP, Account Director; **Valeria Carter**, Senior Medical Strategist; and **Neir Bhalavat**, Senior Medical Strategist. Their in-depth knowledge and active participation at the Congress helped shape our understanding of the latest advancements in oncology.

If you'd like to learn more about these insights or discuss how these trends might impact your organization, please reach out to **Jonathan Gough** at jonathan.gough@wildtypehealth.com